2024
DOI: 10.25259/ajpps_2024_003
|View full text |Cite
|
Sign up to set email alerts
|

Factor Xa inhibitors versus warfarin in severely obese patients with venous thromboembolism or atrial fibrillation

Haley Elizabeth Tierce,
Kathleen Ann Lusk,
Amanda Kristine Kitten
et al.

Abstract: Objectives: Clinical data for the safety and efficacy of Factor Xa (FXa) inhibitors in severely obese patients is limited. Additional information is needed to assess the risks and benefits of using FXa inhibitors in this patient population. Materials and Methods: A single-center and retrospective chart review was conducted in severely obese patients (body mass index [BMI] >40 kg/m2 or weight >120 kg), who received rivaroxaban, apixaban or warfarin for venous thromboembolism (VTE) treatment or preventio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 37 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?